Results 201 to 210 of about 28,066 (219)

S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway

Cell Reports, 2022
Dianyun Ren, Heshui Wu
exaly  

The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition

Expert Review of Clinical Pharmacology, 2022
Massimiliano Ruscica, Amir Abaas Momtazi-Borojeni   +1 more
exaly  

Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9

Journal of Lipid Research, 2021
Hagai Tavori, Paul Mueller, Nathalie Pamir   +2 more
exaly  

Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study

Atherosclerosis, 2020
Alice Bonomi, Daniela Sansaro, Rona J Strawbridge   +2 more
exaly  

Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia

Drug Discovery Today, 2022
Kishor Mohanan, Shakir Ahamad
exaly  

PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia

Basic Research in Cardiology, 2020
Zufeng Ding, Xianwei Wang
exaly  

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

Circulation, 2018
Aaron Aday, Lynda Rose
exaly  

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Proceedings of the National Academy of Sciences of the United States of America, 2008
Kallanthottathil G Rajeev, Jamie Wong, Klaus Charisse   +2 more
exaly  

PCSK9 inhibition and inflammation: A narrative review

Atherosclerosis, 2019
Massimiliano Ruscica, Alberto Corsini
exaly  

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway

Atherosclerosis, 2017
Xi-Long Zheng, Zhihan Tang
exaly